Side-by-side comparison of AI visibility scores, market position, and capabilities
Scribe automatically creates SOPs, training guides, and process documents from screen recordings, turning any workflow into a shareable step-by-step document instantly.
Scribe is a process documentation platform that converts screen recordings into polished, shareable step-by-step guides automatically, capturing every click, keystroke, and navigation event during a workflow and generating a formatted document with annotated screenshots and descriptive step text without any manual authoring. The platform addresses the documentation bottleneck that exists in virtually every knowledge-work organization: the people who know how a process works are the same people who lack time to document it, and the gap between knowing a process and having a written SOP that others can follow is expensive to close manually. Scribe reduces that gap to a single workflow execution, making it practical to document every repeatable task rather than only the highest-priority ones.
No-code website builder reaching $50M ARR in August 2025 at $2B valuation with 500K MAU; used by 40% of YC's latest batch and Perplexity competing with Webflow for design-quality sites.
Framer is a professional no-code website builder and design tool used by marketing teams, startups, and design-led companies to create responsive, interactive websites without writing code — combining the visual fidelity of a design tool (Figma-like precision) with the publishing infrastructure of a CMS, enabling teams to go from design to live website without a separate development handoff. Founded in Amsterdam and backed by $161 million total funding including a $100 million Series D in August 2025 at a $2 billion valuation, Framer reached $50 million ARR in August 2025 (doubling from $25 million in 2024) with 500,000 monthly active users including Miro, Perplexity, Scale AI, and 40% of Y Combinator's latest batch.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.